about
Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide LyP-1.Family characteristics as risk factors for childhood acute lymphoblastic leukemia: a population-based case-control studyInduction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.Exploring the association of hemoglobin level and adverse events in children with cancer presenting with fever in neutropeniaCD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheresA prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study.Health-related quality of life in long-term survivors of relapsed childhood acute lymphoblastic leukemiaNuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomasBackground ionizing radiation and the risk of childhood cancer: a census-based nationwide cohort study.PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemiaGenomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice.Space-Time Clustering of Childhood Leukemia: Evidence of an Association with ETV6-RUNX1 (TEL-AML1) Fusion.Temporal association between childhood leukaemia and population growth in Swiss municipalities.Socioeconomic disparities in childhood cancer survival in Switzerland.Parents' and patients' experiences with paediatric oncology care in Switzerland--satisfaction and some hurdles.FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells.p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study.Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study.Primary Metastatic Synovial Sarcoma: Experience of the CWS Study Group.Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics.Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia.Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.Immune activation suppresses initiation of lytic Epstein-Barr virus infection.Pencil Beam Scanning Proton Therapy for Pediatric Parameningeal Rhabdomyosarcomas: Clinical Outcome of Patients Treated at the Paul Scherrer Institute.Different fever definitions and the rate of fever and neutropenia diagnosed in children with cancer: a retrospective two-center cohort study.Population mixing and the risk of childhood leukaemia in Switzerland: a census-based cohort study.First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.Serious medical complications in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study.Real-time broad-range PCR versus blood culture. A prospective pilot study in pediatric cancer patients with fever and neutropenia.Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000.Prognosis in pediatric hematologic malignancies is associated with serum concentration of mannose-binding lectin-associated serine protease-2 (MASP-2).Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.Port-a-cath-related thrombosis and postthrombotic syndrome in pediatric oncology patients.
P50
Q33397460-FEAB51DE-C971-4927-B5F0-21B4D18AC1FFQ33722035-4959CE04-45EF-49FA-8D65-E5639B968A38Q33755338-4F5C9957-AFE4-4B31-A83B-1FF25722D9E1Q33895962-CEF3C9BE-81CD-4E4D-9775-A2EDC4A8858AQ33908271-C4D1D0DC-658B-4699-9957-EFEB38EA1923Q34065997-F806EA75-5D9E-4A62-9390-8FB11EE55F3EQ34291473-821986B2-FFB5-4F22-9AC9-AAEF3B761722Q34346138-636A7F30-6A1B-4F6A-813D-DACEF4A1586EQ35683239-D0C2BDE4-5C2B-4631-A940-179F10ECD961Q35763861-9AF4D12C-6B80-4A8C-AB5A-C8F13FF99057Q36094717-C525415F-A687-4AF2-AB81-89246F825B2FQ36154689-6FB302F1-8AA7-4640-9575-E53D3789FE80Q36247097-79A90DDD-4D7C-4AED-AA72-3F0FE959A35FQ36262391-C7D9B7D9-F6A8-4B2E-8335-F28D78B067C5Q38859537-211CA54E-FDB7-478F-B4C9-41637CEA52BDQ38859629-D75D11B8-7F13-4476-98FD-8612C4A9044AQ38874561-4659F879-6DA3-49B1-8A4C-98CF56E01829Q39248446-911A81D2-FB9F-43DD-A012-D4493B4D36D5Q39706036-7D03C31F-DCCE-4E37-90A2-48EA74BC52AAQ39773225-F8AEB733-30C3-4FED-95AF-A639BCB1C1D4Q39835436-42105ACE-C4A8-4B98-9998-8D2776B27ECDQ39891473-4949767D-0705-4EA1-9DC8-EC1579AD32B4Q39898636-5296B3C5-2FD3-4245-A614-5001564FF789Q39976938-67A20F88-6543-4007-86D8-A966E6D39542Q40007826-A6E77590-0716-4D6A-88E3-EC7CD3A47F2CQ40126040-977EA6AA-F8E1-415E-A1CA-66F52872F3B9Q40147746-B4F118E2-B9AE-4C32-A4DE-0E4439FBFDA2Q40174533-0036A024-9E82-4B7C-8A16-E6E7DEE3C439Q40266414-A3AA554D-2DD8-48E4-BBBC-9899E0CDC1CEQ40283089-DF23651E-DD99-4ED2-8C7A-32F65A5D05FBQ40298464-07324D22-9BF4-4DAC-803D-4BD61008A5F0Q40315460-2B87850D-37FC-4B29-BBC1-59B9A677C32EQ40456529-DC3D369A-7627-4436-90EF-FF01E1F92BDDQ43102321-37BF9A60-C41F-42FE-98BE-DFCB4329C800Q43162649-B3C5DF0F-3136-43FA-A69A-A362C06F2AC8Q43196412-508DC964-5BFC-47DF-9104-00970593316DQ43495580-F529392C-9FB4-474F-A6B8-0E3C6108E224Q43908406-005DDD9E-2C95-4276-BAF7-354350897D10Q44706813-8A0CF18A-97A9-4F36-B58D-34F05482407FQ45250782-B25C6D3D-C4B1-4E6F-A5E1-2A238EA00816
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Felix K Niggli
@ast
Felix K Niggli
@en
Felix K Niggli
@es
Felix K Niggli
@nl
Felix K Niggli
@sl
type
label
Felix K Niggli
@ast
Felix K Niggli
@en
Felix K Niggli
@es
Felix K Niggli
@nl
Felix K Niggli
@sl
altLabel
Felix Niggli
@en
prefLabel
Felix K Niggli
@ast
Felix K Niggli
@en
Felix K Niggli
@es
Felix K Niggli
@nl
Felix K Niggli
@sl
P1053
L-6547-2017
P106
P21
P31
P3829
P496
0000-0002-7553-3712